129 related articles for article (PubMed ID: 38105153)
1. Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non-Small-Cell Lung Cancer.
Riudavets M; Auclin E; Mosteiro M; Dempsey N; Majem M; Prelaj A; López-Castro R; Bosch-Barrera J; Pilotto S; Escalera E; Tagliamento M; Mosquera J; Zalcman G; Aboubakar Nana F; Ponce S; Albarrán-Artahona V; Dal Maso A; Spotti M; Mielgo X; Mussat E; Reyes R; Benítez JC; Lupinacci L; Duchemann B; De Giglio A; Blaquier JB; Audigier-Valette C; Scheffler M; Nadal E; Lopes G; Signorelli D; Garcia-Campelo R; Menis J; Bluthgen V; Campayo M; Recondo G; Besse B; Mezquita L; Planchard D
Clin Lung Cancer; 2024 May; 25(3):233-243.e8. PubMed ID: 38105153
[TBL] [Abstract][Full Text] [Related]
2. Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer.
Mezquita L; Auclin E; Ferrara R; Charrier M; Remon J; Planchard D; Ponce S; Ares LP; Leroy L; Audigier-Valette C; Felip E; Zerón-Medina J; Garrido P; Brosseau S; Zalcman G; Mazieres J; Caramela C; Lahmar J; Adam J; Chaput N; Soria JC; Besse B
JAMA Oncol; 2018 Mar; 4(3):351-357. PubMed ID: 29327044
[TBL] [Abstract][Full Text] [Related]
3. Plunging Into the PACIFIC: Outcomes of Patients With Unresectable KRAS-Mutated Non-Small Cell Lung Cancer Following Definitive Chemoradiation and Durvalumab Consolidation.
Barsouk A; Friedes C; Iocolano M; Doucette A; Cohen RB; Robinson KW; D'Avella CA; Marmarelis ME; Kosteva JA; Singh AP; Ciunci CA; Levin WP; Cengel KA; Bradley JD; Feigenberg SJ; Sun L; Aggarwal C; Langer CJ; Yegya-Raman N
Clin Lung Cancer; 2024 May; 25(3):e161-e171. PubMed ID: 38195320
[TBL] [Abstract][Full Text] [Related]
4. Durvalumab After Chemoradiotherapy in Patients With Unresectable Stage III Non-Small Cell Lung Cancer.
Mooradian MJ; Cai L; Wang A; Qiao Y; Chander P; Whitaker RM
JAMA Netw Open; 2024 Apr; 7(4):e247542. PubMed ID: 38648057
[TBL] [Abstract][Full Text] [Related]
5. Durvalumab Consolidation After Chemoradiotherapy in Elderly Patients With Unresectable Stage III NSCLC: A Real-World Multicenter Study.
Park JE; Hong KS; Choi SH; Lee SY; Shin KC; Jang JG; Kwon YS; Park SH; Choi KJ; Jung CY; Eom JS; Kim S; Seol HY; Kim J; Kim I; Park JH; Kim TH; Ahn JH
Clin Lung Cancer; 2024 Jun; 25(4):354-364. PubMed ID: 38503590
[TBL] [Abstract][Full Text] [Related]
6. Predicting Immunotherapy Outcomes in Older Patients with Solid Tumors Using the LIPI Score.
Pierro M; Baldini C; Auclin E; Vincent H; Varga A; Martin Romano P; Vuagnat P; Besse B; Planchard D; Hollebecque A; Champiat S; Marabelle A; Michot JM; Massard C; Mezquita L
Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291861
[TBL] [Abstract][Full Text] [Related]
7. Association of the Pretreatment Lung Immune Prognostic Index with Survival Outcomes in Advanced Hepatocellular Carcinoma Patients Treated with PD-1 Inhibitors.
Chen S; Huang Z; Jia W; Tao H; Zhang S; Ma J; Liu Z; Wang J; Wang L; Cui P; Zhang Z; Huang D; Wu Z; Zheng X; Hu Y
J Hepatocell Carcinoma; 2020; 7():289-299. PubMed ID: 33173757
[TBL] [Abstract][Full Text] [Related]
8. Clinical Significance of Serum Biomarkers in Stage IV Non-Small-Cell Lung Cancer Treated with PD-1 Inhibitors: LIPI Score, NLR, dNLR, LMR, and PAB.
Chen J; Wei S; Zhao T; Zhang X; Wang Y; Zhang X
Dis Markers; 2022; 2022():7137357. PubMed ID: 35945957
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Value of the Pretreatment Lung Immune Prognostic Index in Advanced Small Cell Lung Cancer Patients Treated With First-Line PD-1/PD-L1 Inhibitors Plus Chemotherapy.
Li L; Pi C; Yan X; Lu J; Yang X; Wang C; Li X; Zhang S; Zhang Z; Sun Y; Hu Y
Front Oncol; 2021; 11():697865. PubMed ID: 34692478
[TBL] [Abstract][Full Text] [Related]
10. Prognosis stratification of cancer patients treated with immune checkpoint inhibitors through lung immune prognostic index: a meta-analysis and systematic review.
Guo Y; Pan Y; Wan J; Gong B; Li Y; Kan X; Zheng C
BMC Cancer; 2024 Apr; 24(1):523. PubMed ID: 38664760
[TBL] [Abstract][Full Text] [Related]
11. A validation study on the lung immune prognostic index for prognostic value in patients with locally advanced non-small cell lung cancer.
Zhang T; Xue W; Wang D; Xu K; Wu L; Wu Y; Zhou Z; Chen D; Feng Q; Liang J; Xiao Z; Hui Z; Lv J; Wang X; Deng L; Wang W; Liu W; Wang J; Zhai Y; Wang J; Bi N; Wang L
Radiother Oncol; 2021 Mar; 156():244-250. PubMed ID: 33418003
[TBL] [Abstract][Full Text] [Related]
12. Validation of the Lung Immune Prognostic Index (LIPI) as a prognostic biomarker in metastatic renal cell carcinoma.
Carril-Ajuria L; Lavaud P; Dalban C; Negrier S; Gravis G; Motzer RJ; Chevreau C; Tannir NM; Oudard S; McDermott DF; Laguerre B; Hammers HJ; Barthelemy P; Plimack ER; Borchiellini D; Gross-Goupil M; Jiang R; Lee CW; de Silva H; Rini BI; Escudier B; Albigès L
Eur J Cancer; 2024 Jun; 204():114048. PubMed ID: 38653033
[TBL] [Abstract][Full Text] [Related]
13. Association of the pretreatment lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced hepatocellular carcinoma.
Sun T; Guo Y; Sun B; Chen L; Ren Y; Zhu L; Zhang L; Liu Y; Zheng C
Eur J Med Res; 2023 Jul; 28(1):225. PubMed ID: 37408056
[TBL] [Abstract][Full Text] [Related]
14. Association of the pretreatment lung immune prognostic index with survival outcomes in advanced gastric cancer patients treated with immune checkpoint inhibitors.
Hou B; Wang P; Liu T; Chen S; Li T; Zhang S; Tao H; Li X; Hu Y
Clin Res Hepatol Gastroenterol; 2021 Sep; 45(5):101748. PubMed ID: 34182184
[TBL] [Abstract][Full Text] [Related]
15. Pretreatment Lung Immune Prognostic Index Is a Prognostic Marker of Chemotherapy and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor.
Minami S; Ihara S; Komuta K
World J Oncol; 2019 Feb; 10(1):35-45. PubMed ID: 30834050
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Value of the Lung Immune Prognostic Index for Patients Treated for Metastatic Non-Small Cell Lung Cancer.
Kazandjian D; Gong Y; Keegan P; Pazdur R; Blumenthal GM
JAMA Oncol; 2019 Oct; 5(10):1481-1485. PubMed ID: 31343662
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Predictive and Prognostic Importance of Lung Immune Prognostic Index in Locally Advanced Rectal Cancer Patients Treated With Neoadjuvant Chemoradiotherapy.
Arıkan R; Alkış H; Işık S; Yaşar A; Çelebi A; Majidova N; Sever N; Adlı M; Demircan NC
Cureus; 2023 Jun; 15(6):e40548. PubMed ID: 37465788
[TBL] [Abstract][Full Text] [Related]
18. [Effect of dNLR and LIPI scores on the prognosis of elderly patients with non-surgical treatment of non-small cell lung cancer].
Xie JH; Liu MM; Sun NN; Zhang L; Zhang HZ
Zhonghua Zhong Liu Za Zhi; 2022 Sep; 44(9):975-980. PubMed ID: 36164700
[No Abstract] [Full Text] [Related]
19. Real-World Data on Pembrolizumab for Pretreated Non-Small-Cell Lung Cancer: Clinical Outcome and Relevance of the Lung Immune Prognostic Index.
Ortega-Franco A; Hodgson C; Raja H; Carter M; Lindsay C; Hughes S; Cove-Smith L; Taylor P; Summers Y; Blackhall F; Califano R
Target Oncol; 2022 Jul; 17(4):453-465. PubMed ID: 35781861
[TBL] [Abstract][Full Text] [Related]
20. Pretreatment lung immune prognostic index as a biomarker in advanced non-small-cell lung cancer patients receiving first line pembrolizumab.
Veccia A; Sforza V; Vattemi E; Inno A; Kinspergher S; Dipasquale M; Gori S; Morabito A; Baldi I; Caffo O
Immunotherapy; 2021 Sep; 13(13):1093-1103. PubMed ID: 34190578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
